Overview

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

Status:
Terminated

Trial end date:
2021-04-13

Target enrollment:
0

Participant gender:
All

Summary

This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Galapagos NV

Criteria

Inclusion Criteria:

- Male or female subjects who completed the 24-week treatment period of Study
GLPG1690-CL-204 and who according to the investigator's judgment may benefit from
long-term treatment with GLPG1690.

Exclusion Criteria:

- Any condition or circumstances that, in the opinion of the investigator, may make a
subject unlikely or unable to complete the study or comply with study procedures and
requirements.